Marcel Levi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3454773/publications.pdf

Version: 2024-02-01

221 papers	27,262 citations	11235 73 h-index	7043 159 g-index
223 all docs	223 docs citations	223 times ranked	26721 citing authors

#	Article	IF	Citations
1	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. Thrombosis and Haemostasis, 2022, 122, 008-019.	1.8	11
2	Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARSâ€CoVâ€2 vaccination. European Journal of Neurology, 2022, 29, 339-344.	1.7	38
3	Tocilizumab in severe COVID-19: A promise fulfilled. European Journal of Internal Medicine, 2022, 95, 38-39.	1.0	5
4	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respiratory Medicine,the, 2022, 10, 214-220.	5.2	37
5	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. Journal of Intensive Care, 2022, 10, 4.	1.3	0
6	Surprising outcomes of general internal medicine care versus specialty care in acutely admitted medical patients. European Journal of Internal Medicine, 2022, , .	1.0	1
7	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. EClinicalMedicine, 2022, 44, 101276.	3.2	21
8	Prophylaxis with anti-activated factor XII for hereditary angioedema. Lancet, The, 2022, 399, 889-890.	6.3	2
9	COVID-19 associated coagulopathy and thrombosis in cancer. Thrombosis Research, 2022, 213, S72-S76.	0.8	1
10	Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp>â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	2.8	21
11	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. European Journal of Internal Medicine, 2021, 83, 34-38.	1.0	25
12	Pharyngeal Antisepsis to Reduce COVID-19 Pneumonia. American Journal of Medicine, 2021, 134, 297-298.	0.6	0
13	Aortic thrombosis in COVID-19. Clinical Infection in Practice, 2021, 9, 100059.	0.2	8
14	Should NHS managers be regulated like doctors?. BMJ, The, 2021, 372, m4909.	3.0	1
15	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	1.0	12
16	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021, 21, 319-329.	10.6	594
17	Vascular mechanisms and manifestations of COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 551-553.	5.2	13
18	Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19. HemaSphere, 2021, 5, e571.	1.2	9

#	Article	IF	Citations
19	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 384, 2202-2211.	13.9	795
20	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 332.	3.8	37
21	Postâ€SARSâ€CoVâ€2â€vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. European Journal of Neurology, 2021, 28, 3656-3662.	1.7	84
22	COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4156-4158.	2.0	15
23	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	1.2	3
24	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	1.0	83
25	COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Internal and Emergency Medicine, 2021, 16, 309-312.	1.0	68
26	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2020, 46, 089-095.	1.5	124
27	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.4	0
28	Relevance and diagnosis of disseminated intravascular coagulation associated with cardiovascular disease. European Journal of Internal Medicine, 2020, 79, 27-28.	1.0	0
29	COVID-19: a complex multisystem disorder. British Journal of Anaesthesia, 2020, 125, 238-242.	1.5	108
30	An overview of thrombotic complications of old and new anticancer drugs. Thrombosis Research, 2020, 191, S17-S21.	0.8	14
31	Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Critical Care Medicine, 2020, 48, 1140-1147.	0.4	34
32	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	1.9	69
33	The authors reply. Critical Care Medicine, 2020, 48, e1160-e1161.	0.4	7
34	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. New England Journal of Medicine, 2020, 383, 1242-1247.	13.9	28
35	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	1.9	16
36	Coagulopathy of Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1358-1364.	0.4	412

#	Article	IF	Citations
37	Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. European Journal of Internal Medicine, 2020, 76, 21-22.	1.0	15
38	Re The source of elevated plasma Dâ€dimer levels in COVIDâ€19 infection. British Journal of Haematology, 2020, 190, e133-e134.	1.2	46
39	Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology,the, 2020, 7, e438-e440.	2.2	1,186
40	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1859-1865.	1.9	547
41	COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Advances, 2020, 4, 2850-2850.	2.5	46
42	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€induced coagulopathy than fibrinâ€related markers: Response to the Letterâ€toâ€theâ€Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	1.9	1
43	Coagulopathy in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2103-2109.	1.9	453
44	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	2.5	366
45	Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathyâ€”Either, Neither, or Both. Seminars in Thrombosis and Hemostasis, 2020, 46, 781-784.	1.5	74
46	ISTH interim guidance on recognition and management of coagulopathy in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1023-1026.	1.9	1,513
47	JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. European Respiratory Journal, 2020, 56, 2001919.	3.1	52
48	Thrombosis and coagulopathy in COVIDâ€19: An illustrated review. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 744-751.	1.0	49
49	Why industrial methods do not work in healthcare: an analytical approach. Internal Medicine Journal, 2020, 50, 250-253.	0.5	4
50	Type and dose of heparin in Covidâ€19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 2063-2064.	1.9	19
51	DOACs and â€œenewerâ€•hemophilia therapies in COVIDâ€19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 1795-1796.	1.9	17
52	Laboratory haemostasis monitoring in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2058-2060.	1.9	25
53	Strengths and weaknesses of the acute care systems in the United Kingdom and the Netherlands: what can we learn from each other?. BMC Emergency Medicine, 2019, 19, 40.	0.7	9
54	Coagulation and anticoagulation in the intraoperative setting. Transfusion and Apheresis Science, 2019, 58, 386-391.	0.5	5

#	Article	IF	Citations
55	Diagnosis and management of sepsisâ€induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1989-1994.	1.9	325
56	The Role of Complement in Hereditary Angioedema. Transfusion Medicine Reviews, 2019, 33, 243-247.	0.9	11
57	Involving medical students in service improvement: evaluation of a student-led, extracurricular, multidisciplinary quality improvement initiative . Advances in Medical Education and Practice, 2019, Volume 10, 781-793.	0.7	5
58	Hereditary angioedema: Linking complement regulation to the coagulation system. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 38-43.	1.0	26
59	Proposal of a twoâ€step process for the diagnosis of sepsisâ€induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	1.9	37
60	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy. JAMA - Journal of the American Medical Association, 2019, 321, 1993.	3.8	221
61	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thrombosis Research, 2019, 179, 11-14.	0.8	41
62	Disseminated Intravascular Coagulation in Cancer: An Update. Seminars in Thrombosis and Hemostasis, 2019, 45, 342-347.	1.5	50
63	Albumin plasma exchange for life-threatening angioedema with normal C1-inhibitor. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1360-1361.	2.0	2
64	Longâ€term effects upon rituximab treatment of acquired angioedema due to C1â€inhibitor deficiency. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 834-840.	2.7	12
65	How I treat disseminated intravascular coagulation. Blood, 2018, 131, 845-854.	0.6	173
66	Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thrombosis Research, 2018, 164, S77-S81.	0.8	29
67	Hemostasis and Thrombosis in Extreme Temperatures (Hypo- and Hyperthermia). Seminars in Thrombosis and Hemostasis, 2018, 44, 651-655.	1.5	24
68	Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Review of Hematology, 2018, 11, 663-672.	1.0	87
69	Generalism in modern subspecializing medicine. European Journal of Internal Medicine, 2017, 39, 36-38.	1.0	7
70	What do sepsis-induced coagulation test result abnormalities mean to intensivists?. Intensive Care Medicine, 2017, 43, 581-583.	3.9	13
71	Point-of-Care Testing in Acute Hemorrhagic and Thrombotic States. Seminars in Thrombosis and Hemostasis, 2017, 43, 364-366.	1.5	4
72	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. Thrombosis Research, 2017, 159, 96-99.	0.8	11

#	Article	IF	Citations
73	Coagulation and sepsis. Thrombosis Research, 2017, 149, 38-44.	0.8	547
74	Nebulized anticoagulants in lung injury in critically ill patientsâ€"an updated systematic review of preclinical and clinical studies. Annals of Translational Medicine, 2017, 5, 444-444.	0.7	36
75	Platelets in Critical Illness. Seminars in Thrombosis and Hemostasis, 2016, 42, 252-257.	1.5	47
76	Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Annals of Medicine, 2016, 48, 256-267.	1.5	55
77	Management of cancer-associated disseminated intravascular coagulation. Thrombosis Research, 2016, 140, S66-S70.	0.8	42
78	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood, 2016, 127, 1417-1425.	0.6	156
79	Management of bleeding in patients treated with direct oral anticoagulants. Critical Care, 2016, 20, 249.	2.5	20
80	Engineering Reversal â€" Finding an Antidote for Direct Oral Anticoagulants. New England Journal of Medicine, 2016, 375, 1185-1186.	13.9	12
81	Disseminated intravascular coagulation. Nature Reviews Disease Primers, 2016, 2, 16037.	18.1	367
82	Antithrombin: anti-inflammatory properties and clinical applications. Thrombosis and Haemostasis, 2016, 115, 712-728.	1.8	138
83	Supportive management strategies for disseminated intravascular coagulation. Thrombosis and Haemostasis, 2016, 115, 896-904.	1.8	65
84	The role of ADAMTS13 in acute myocardial infarction: cause or consequence?. Cardiovascular Research, 2016, 111, 194-203.	1.8	24
85	What Other Industries Can Learn From Health Care. JAMA Internal Medicine, 2016, 176, 425.	2.6	3
86	Whatâ€™s new in the diagnostic criteria of disseminated intravascular coagulation?. Intensive Care Medicine, 2016, 42, 1062-1064.	3.9	24
87	Emergency Reversal Strategies for Anticoagulation and Platelet Disorders. Frontiers of Neurology and Neuroscience, 2015, 37, 51-61.	3.0	1
88	Post-authorisation assessment of orphan drugs. Lancet, The, 2015, 386, 1940-1941.	6.3	11
89	Hemostatic abnormalities in critically ill patients. Internal and Emergency Medicine, 2015, 10, 287-296.	1.0	16
90	The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis. Thrombosis Research, 2015, 135, 537-543.	0.8	12

#	Article	IF	Citations
91	Coagulation in Patients with Severe Sepsis. Seminars in Thrombosis and Hemostasis, 2015, 41, 009-015.	1.5	114
92	Thrombosis and Hemostasis Issues in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2015, 41, 007-008.	1.5	5
93	Common genetic variants do not associate with CAD in familial hypercholesterolemia. European Journal of Human Genetics, 2014, 22, 809-813.	1.4	2
94	The Potential Therapeutic Benefit of Targeting ADAMTS13 Activity. Seminars in Thrombosis and Hemostasis, 2014, 40, 028-033.	1.5	15
95	A Short Contemporary History of Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2014, 40, 874-880.	1.5	64
96	Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. Cmaj, 2014, 186, E547-E556.	0.9	138
97	New Oral Anticoagulantâ€“Induced Bleeding. Clinics in Laboratory Medicine, 2014, 34, 575-586.	0.7	17
98	Universal definition of perioperative bleeding in adult cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1458-1463.e1.	0.4	301
99	Cancer-related coagulopathies. Thrombosis Research, 2014, 133, S70-S75.	0.8	44
100	Recombinant Human Activated Protein C in the Treatment of Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. PLoS ONE, 2014, 9, e90983.	1.1	32
101	Pathogenesis and management of peripartum coagulopathic calamities (disseminated intravascular) Tj ETQq1 1 0.784314 rgBT /Over	0.8	32
102	New Fundamentals in Hemostasis. Physiological Reviews, 2013, 93, 327-358.	13.1	817
103	Disseminated intravascular coagulation: a review for the internist. Internal and Emergency Medicine, 2013, 8, 23-32.	1.0	79
104	Endothelial injury in sepsis. Intensive Care Medicine, 2013, 39, 1839-1842.	3.9	53
105	Disease-Specific Thrombosis. Seminars in Thrombosis and Hemostasis, 2013, 39, 459-460.	1.5	1
106	Sepsis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2013, 39, 559-566.	1.5	175
107	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*. Critical Care Medicine, 2013, 41, 2069-2079.	0.4	423
108	Should antifibrinolytics be given in all patients with trauma?. Current Opinion in Anaesthesiology, 2012, 25, 385-388.	0.9	7

#	Article	IF	Citations
109	Safety of Prohemostatic Interventions. Seminars in Thrombosis and Hemostasis, 2012, 38, 292-298.	1.5	6
110	Infection and Inflammation as Risk Factors for Thrombosis and Atherosclerosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 506-514.	1.5	85
111	Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Seminars in Immunopathology, 2012, 34, 167-179.	2.8	72
112	Dabigatran led to less major bleeding than warfarin in younger but not older patients with atrial fibrillation. Annals of Internal Medicine, 2011, 155, JC3.	2.0	2
113	DIC: Which laboratory tests are most useful. Blood Reviews, 2011, 25, 33-37.	2.8	126
114	Hematologic Failure. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 651-660.	0.8	2
115	Factor V Leiden Mutation in Severe Infection and Sepsis. Seminars in Thrombosis and Hemostasis, 2011, 37, 955-960.	1.5	8
116	Forgotten Factors in Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2011, 37, 337-338.	1.5	0
117	2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy, Asthma and Clinical Immunology, 2010, 6, 24.	0.9	443
118	Inflammation and coagulation. Critical Care Medicine, 2010, 38, S26-S34.	0.4	733
119	Disseminated Intravascular Coagulation: A Disease-Specific Approach. Seminars in Thrombosis and Hemostasis, 2010, 36, 363-365.	1.5	22
120	Recombinant Anticoagulant Factors for Adjunctive Treatment of Sepsis. Seminars in Thrombosis and Hemostasis, 2010, 36, 550-557.	1.5	15
121	Disseminated Intravascular Coagulation in Infectious Disease. Seminars in Thrombosis and Hemostasis, 2010, 36, 367-377.	1.5	95
122	Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. New England Journal of Medicine, 2010, 363, 1791-1800.	13.9	655
123	Adequate thromboprophylaxis in critically ill patients. Critical Care, 2010, 14, 142.	2.5	12
124	Treatment with recombinant human activated protein C: one size does not fit all. Critical Care, 2010, 15, 105.	2.5	1
125	Prothrombin Complex Concentrate Reverses the Anticoagulant Effect of Rivaroxaban In Healthy Volunteers.. Blood, 2010, 116, 1094-1094.	0.6	4
126	Improving Antithrombotic Management in Patients With Atrial Fibrillation: Current Status and Perspectives. Seminars in Thrombosis and Hemostasis, 2009, 35, 527-542.	1.5	27

#	Article	IF	Citations
127	Antithrombotic Management of Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 525-526.	1.5	1
128	Management Strategies for Optimal Control of Anticoagulation in Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 560-567.	1.5	17
129	Emergency reversal of antithrombotic treatment. Internal and Emergency Medicine, 2009, 4, 137-145.	1.0	55
130	Disseminated intravascular coagulation in cancer patients. Best Practice and Research in Clinical Haematology, 2009, 22, 129-136.	0.7	80
131	Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period. Thrombosis Research, 2009, 123, S63-S64.	0.8	200
132	Pharmacological Characterization and Structure Activity Relationship of FXI Antisense Oligonucleotides in Cynomolgus Monkeys.. Blood, 2009, 114, 2101-2101.	0.6	0
133	Combination of FXI Antisense Oligonucleotide and PlavixÂ® Treatment Results in Enhanced Antithrombotic Activity without Increased Risk of Bleeding in Mouse Models of Thrombosis.. Blood, 2009, 114, 4173-4173.	0.6	0
134	The Coagulant Response in Sepsis. Clinics in Chest Medicine, 2008, 29, 627-642.	0.8	108
135	Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema. Clinical Therapeutics, 2008, 30, 2314-2323.	1.1	46
136	Self-management of anticoagulation. Expert Review of Cardiovascular Therapy, 2008, 6, 979-985.	0.6	15
137	The inflammationâ€“coagulation axis as an important intermediate pathway in acute lung injury. Critical Care, 2008, 12, 144.	2.5	13
138	Sepsis, Coagulation, and Antithrombin: Old Lessons and New Insights. Seminars in Thrombosis and Hemostasis, 2008, 34, 742-746.	1.5	49
139	The Role of Natural Anticoagulants in the Pathogenesis and Management of Systemic Activation of Coagulation and Inflammation in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2008, 34, 459-468.	1.5	123
140	Hemostasis and Thrombosis in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2008, 34, 415-416.	1.5	2
141	Metabolic Modulation of Inflammation-Induced Activation of Coagulation. Seminars in Thrombosis and Hemostasis, 2008, 34, 026-032.	1.5	36
142	Thrombocytopenia in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2008, 34, 417-424.	1.5	81
143	Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood, 2008, 111, 4471-4476.	0.6	94
144	Activated protein C in sepsis: a critical review. Current Opinion in Hematology, 2008, 15, 481-486.	1.2	41

#	Article	IF	Citations
145	Severe Malaria and Leptospirosis Are Associated with a Deficiency of the Von Willebrand Factor Cleaving Protease, ADAMTS13. Blood, 2008, 112, 3912-3912.	0.6	2
146	Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). American Journal of Respiratory and Critical Care Medicine, 2007, 176, 483-490.	2.5	164
147	Disseminated intravascular coagulation. Critical Care Medicine, 2007, 35, 2191-2195.	0.4	485
148	Recombinant human activated protein C: current insights into its mechanism of action. Critical Care, 2007, 11, S3.	2.5	51
149	Prevention and Treatment of Major Blood Loss. New England Journal of Medicine, 2007, 356, 2301-2311.	13.9	445
150	Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion, 2007, 47, 1028-1032.	0.8	85
151	Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2006, 117, 904-908.	1.5	161
152	Plasma and plasma components in the management of disseminated intravascular coagulation. Best Practice and Research in Clinical Haematology, 2006, 19, 127-142.	0.7	23
153	Coagulation abnormalities in critically ill patients. Critical Care, 2006, 10, 222.	2.5	252
154	Rituximab-induced Elimination of Acquired Angioedema Due to C1-Inhibitor Deficiency. American Journal of Medicine, 2006, 119, e3-e5.	0.6	58
155	Tissue Factor in Infection and Severe Inflammation. Seminars in Thrombosis and Hemostasis, 2006, 32, 033-039.	1.5	107
156	Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events. Evidence-Based Medicine, 2006, 11, 59-59.	0.6	1
157	Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Critical Care Medicine, 2005, 33, 883-890.	0.4	302
158	Platelets. Critical Care Medicine, 2005, 33, S523-S525.	0.4	22
159	Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure*. Critical Care Medicine, 2005, 33, 341-348.	0.4	256
160	Two-Way Interactions Between Inflammation and Coagulation. Trends in Cardiovascular Medicine, 2005, 15, 254-259.	2.3	267
161	Pulmonary coagulation and fibrinolysis in acute lung injury and pneumonia. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 3-10.	0.1	0
162	Platelets in sepsis. Hematology, 2005, 10, 129-131.	0.7	62

#	Article	IF	Citations
163	Disseminated Intravascular Coagulation: What's New?. Critical Care Clinics, 2005, 21, 449-467.	1.0	98
164	Antithrombin in sepsis revisited. Critical Care, 2005, 9, 624.	2.5	20
165	New antithrombotics in the treatment of thromboembolic disease. European Journal of Internal Medicine, 2005, 16, 230-237.	1.0	15
166	A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 2005, 116, 876-883.	1.5	121
167	A Reduced Capacity To Generate Activated Protein C and the Role of PAI-1 Deficiency on Coagulation Activation and Fibrin Formation during Murine Influenza Pneumonia.. Blood, 2005, 106, 2134-2134.	0.6	0
168	Pulmonary coagulation and fibrinolysis in acute lung injury and pneumonia. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 3-10.	0.1	0
169	Current understanding of disseminated intravascular coagulation. British Journal of Haematology, 2004, 124, 567-576.	1.2	146
170	Coagulation in sepsis: all bugs bite equally. Critical Care, 2004, 8, 99.	2.5	33
171	Bidirectional Relation Between Inflammation and Coagulation. Circulation, 2004, 109, 2698-2704.	1.6	794
172	New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Annals of Medicine, 2004, 36, 41-49.	1.5	123
173	Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in Hematology, 2004, 41, 65-69.	1.8	52
174	Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation*. Critical Care Medicine, 2004, 32, 2416-2421.	0.4	419
175	Beyond sepsis: Activated protein C and ischemiaâ€“reperfusion injury. Critical Care Medicine, 2004, 32, S309-S312.	0.4	21
176	Sepsis and Disseminated Intravascular Coagulation. Journal of Thrombosis and Thrombolysis, 2003, 16, 43-47.	1.0	143
177	Prevention and Treatment of Bleeding by Pro-hemostatic Treatment Strategies. Wiener Medizinische Wochenschrift, 2003, 153, 421-425.	0.5	12
178	Infection and inflammation and the coagulation system. Cardiovascular Research, 2003, 60, 26-39.	1.8	403
179	Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Critical Care Medicine, 2003, 31, S238-S242.	0.4	147
180	Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-Câ€“deficient mice. Blood, 2003, 101, 4823-4827.	0.6	154

#	Article	IF	Citations
181	Therapeutic Options in Patients with DIC and Cancer. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 46-47.	0.5	7
182	Cancer and thrombosis. Clinical Advances in Hematology and Oncology, 2003, 1, 668-71.	0.3	7
183	Coagulation: Consultative Hemostasis. Hematology American Society of Hematology Education Program, 2002, 2002, 335-352.	0.9	45
184	Endothelium: Interface between coagulation and inflammation. Critical Care Medicine, 2002, 30, S220-S224.	0.4	145
185	Drotrecogin Alfa (Activated). Drugs, 2002, 62, 631-632.	4.9	1
186	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. Journal of Clinical Oncology, 2002, 20, 1657-1667.	0.8	235
187	The diagnosis of disseminated intravascular coagulation. Blood Reviews, 2002, 16, 217-223.	2.8	82
188	Therapeutic intervention in disseminated intravascular coagulation: have we made any progress in the last millennium?. Blood Reviews, 2002, 16 Suppl 1, S29-34.	2.8	2
189	Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction. Circulation, 2001, 104, 3063-3068.	1.6	195
190	Effects of different plasma substitutes on blood coagulation: A comparative review. Critical Care Medicine, 2001, 29, 1261-1267.	0.4	289
191	Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. Thrombosis and Haemostasis, 2001, 86, 1327-1330.	1.8	1,875
192	Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. American Journal of Hematology, 2001, 66, 292-294.	2.0	62
193	Deficiency of Urokinase-Type Plasminogen Activatorâ€“Mediated Plasmin Generation Impairs Vascular Remodeling During Hypoxia-Induced Pulmonary Hypertension in Mice. Circulation, 2001, 103, 2014-2020.	1.6	58
194	Mouse models of focal arterial and venous thrombosis. Basic Research in Cardiology, 2000, 95, 503-509.	2.5	31
195	Editorial. Cardiovascular Research, 1999, 41, 21-24.	1.8	18
196	Beneficial Effects of Conversion From Cyclosporine to Azathioprine on Fibrinolysis in Renal Transplant Recipients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1555-1558.	1.1	28
197	Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nature Medicine, 1999, 5, 107-111.	15.2	123
198	Pathogenesis of DIC in Sepsis. Sepsis, 1999, 3, 103-109.	0.5	8

#	Article	IF	Citations
199	Disseminated Intravascular Coagulation. New England Journal of Medicine, 1999, 341, 586-592.	13.9	1,545
200	Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet, The, 1999, 354, 1940-1947.	6.3	527
201	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ^' > A mutation. , 1998, 44, 427-430.		1
202	Current Drug Treatment Strategies for Disseminated Intravascular Coagulation. Drugs, 1998, 55, 767-777.	4.9	72
203	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ^' > A mutation. , 1998, 44, 427.		1
204	Interleukin-10 Inhibits Activation of Coagulation and Fibrinolysis During Human Endotoxemia. Blood, 1997, 89, 2701-2705.	0.6	145
205	Differential Effects of Reconstituted High-density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia. Thrombosis and Haemostasis, 1997, 77, 303-307.	1.8	79
206	Apolipoprotein(a) Attenuates Endogenous Fibrinolysis in the Rabbit Jugular Vein Thrombosis Model In Vivo. Circulation, 1997, 96, 1612-1615.	1.6	42
207	Fat Emulsion Infusion Potentiates Coagulation Activation during Human Endotoxemia. Thrombosis and Haemostasis, 1996, 75, 083-086.	1.8	28
208	Factor XIa Induced Activation of the Intrinsic Cascade In Vivo. Thrombosis and Haemostasis, 1996, 75, 445-449.	1.8	15
209	Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans. Thrombosis and Haemostasis, 1996, 76, 738-742.	1.8	229
210	Cyclosporin A Impairs the Nocturnal Blood Pressure Fall in Renal Transplant Recipients. Hypertension, 1996, 28, 304-307.	1.3	51
211	Plasminogen Activator and Plasminogen Activator Inhibitor I Release during Experimental Endotoxaemia in Chimpanzees: Effect of Interventions in the Cytokine and Coagulation Cascades. Clinical Science, 1995, 88, 587-594.	1.8	182
212	Complete Inhibition of Endotoxin-Induced Coagulation Activation in Chimpanzees with a Monoclonal Fab Fragment against Factor VII/VIIa. Thrombosis and Haemostasis, 1995, 73, 223-230.	1.8	113
213	A review of studies of the activation of the blood coagulation mechanism in chimpanzees (<i>Pan) Tj ETQq1 1 0.784314 rgBT /Overlo	0.3	2
214	Additive Effect of the Combined Administration of Low Molecular Weight Heparin and Recombinant Hirudin on Thrombus Growth in a Rabbit Jugular Vein Thrombosis Model. Thrombosis and Haemostasis, 1994, 72, 377-380.	1.8	4
215	Assessment of the Relative Contribution of Different Protease Inhibitors to the Inhibition of Plasmin In Vivo. Thrombosis and Haemostasis, 1993, 69, 141-146.	1.8	56
216	Plasminogen Activation In Vivo upon Intravenous Infusion of DDAVP. Thrombosis and Haemostasis, 1992, 67, 111-116.	1.8	82

#	Article	IF	Citations
217	Variable Effects of Radiological Contrast Media on Thrombus Growth in a Rabbit Jugular Vein Thrombosis Model. Thrombosis and Haemostasis, 1991, 66, 218-221.	1.8	16
218	Deep Vein Thrombosis and Fibrinolysis. Thrombosis and Haemostasis, 1991, 66, 426-429.	1.8	17
219	DDAVP Induces Systemic Release of Urokinase-Type Plasminogen Activator. Thrombosis and Haemostasis, 1989, 62, 686-689.	1.8	33
220	Inflammation and Coagulation. , 0, , 833-860.		2
221	A Dutchman in London: reflections of a hospital chief executive from the Netherlands in the NHS. BMJ Leader, 0, , leader-2021-000509.	0.8	0